

5

ABSTRACT OF THE DISCLOSURE

This invention provides pharmaceutically active enantiomers of the
venlafaxine metabolite O-Desmethyl venlafaxine, R(-)-4-[2-(Dimethylamino)-1-(1-
10 hydroxycyclo-hexyl)ethyl]phenol or R(-)-1-[2-(dimethylamino)-1-(4-
hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-
hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-
hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or
salt hydrates thereof, as well as pharmaceutical compositions utilizing these
15 enantiomers and methods of using the enantiomers to treat, inhibit or control central
nervous system disorders.